

## **JAMES SIGNOROVITCH, PH.D.**

### **Managing Principal**

Phone: 617 425 8258  
Fax: 617 425 8001  
james.signorovitch@analysisgroup.com

111 Huntington Avenue  
14th Floor  
Boston, MA 02199

Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch's practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch's work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.

### **EDUCATION**

2007                      Ph.D., biostatistics, Harvard University  
2002                      B.A., biology, Cornell University

### **PROFESSIONAL EXPERIENCE**

2008–Present            Analysis Group, Inc.  
                                 *Managing Principal (2017–Present)*  
                                 *Vice President (2013–2017)*  
2007                      Massachusetts Institute of Technology  
                                 *Research Fellow & Instructor in Biomedical Decision Making*

### **ARTICLES & PUBLICATIONS**

“Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation.” Kponee-Shovein K, Marvel J, Ishikawa R, Choubey A, Kaur H, Ngom K, Fakih I, Swartz N, Schatzki T, Signorovitch J. *Journal of Medical Economics* 2022 Jan-Dec; 25(1): 940-953. e-pub ahead of print 2022/06/11; doi: 10.1080/13696998.2022.2088196.

“Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.” Proudman D, DeVito NC, Belinson S, Allo MA, Morris ED, Signorovitch J, Patel AK. *Journal of Medical Economics* 2022 Jan-Dec; 25(1): 817-825. e-pub ahead of print 2022/05/21; doi: 10.1080/13696998.2022.2080463.

“Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data.” Pivneva I, Balp MM, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang Y, Cornwall T, Pan J, Danyliv A, McKenna SJ, Marsland AM, Soong W. *Dermatology and Therapy (Heidelberg)* 2022 Dec; 12(12): 2747-2763. e-pub ahead of print 2022/10/28; doi: 10.1007/s13555-022-00827-6.

“Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.” Sundaram M, Song Y, Rogerio JW, Zhang S, Bhattacharya R, Adejoro O, Carley C, Zhu JJ, Signorovitch J, Haas NB. *Journal of Managed Care & Specialty Pharmacy* 2022 Oct; 28(10): 1149-1160. e-pub ahead of print 2022/09/02; doi: 10.18553/jmcp.2022.22133.

“Long-Term Treatment Effects of Inotersen on Health-Related Quality of Life in Patients with hATTR Amyloidosis with Polyneuropathy: Analysis of the Open-Label Extension of the NEURO-TTR Trial.” Karam C, Brown D, Yang M, Done N, Zhu JJ, Greatsinger A, Bozas A, Vera-Llonch M, Signorovitch J. *Muscle & Nerve* 2022 Oct; 66(4): 438-446. e-pub ahead of print 2022/07/09; doi: 10.1002/mus.27675.

“Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.” Hu T, Song Y, Done N, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T. *BMC Public Health* 2022 Sep; 22(1): 1677. e-pub ahead of print 2022/09/06; doi: 10.1186/s12889-022-14051-6.

“PIK3CA mutation status, progression and survival in advanced HR +/HER2- breast cancer: a meta-analysis of published clinical trials.” Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, Park J, Dua A, Rugo HS. *BMC Cancer* 2022 Sep; 22(1): 1002. e-pub ahead of print 2022/09/22; doi: 10.1186/s12885-022-10078-5.

“Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation with Omidubicel versus Standard Umbilical Cord Blood.” Lin C, Sajeev G, Stiff P, Brunstein C, Cutler C, Sanz G, Lindemans C, Rezvani A, Hanna R, Koh LP, Maziarz R, Hwang W, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Horwitz M, Sung A. *Transplantation and Cellular Therapy* 2022 Sep 28; S2666-6367(22)01655-4. doi: 10.1016/j.jtct.2022.09.018.

“Factors Associated with Increased Health-Related Quality of Life Benefits in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) Treated with Inotersen.” Karam C, Brown D, Yang M, Done N, Dieye I, Bozas A, Vera Llonch M, Signorovitch J. *Muscle & Nerve* 2022 Sep; 66(3): 319-328. e-pub ahead of print 2022/06/30; doi: 10.1002/mus.27668.

“Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study.” Greene SJ, Lautsch D, Gaggin HK, Djatche LM, Zhou M, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. *American Heart Journal* 2022 Sep: 127-136. e-pub ahead of print 2022/06/01; doi: 10.1016/j.ahj.2022.05.016.

“Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata.” Ray M, Swallow E, Gandhi K, Carley C, Sikirica V, Wang T, Done N, Signorovitch J, Mostaghimi A. *Journal of Health Economics and Outcomes Research* 2022 Aug; 9(2): 11-18. e-pub ahead of print 2022/08/18; doi: 10.36469/001c.36229.

“Carbon footprint and associated costs of asthma exacerbation care among UK adults.” Kponee-Shovein K, Marvel J, Ishikawa R, Choubey A, Kaur H, Thokala P, Ngom K, Fakih I, Schatzki T, Signorovitch J.

*Journal of Medical Economics* 2022 Apr; 1-23. e-pub ahead of print 2022/04/14; doi: 10.1080/13696998.2022.2063603.

“Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma.” Signorovitch J, Moshyk A, Zhao J, Le TK, Burns L, Gooden K, Hamilton M. *Future Oncology* 2022 Apr; 18(11): 1321-1331. e-pub ahead of print 2022/01/21; doi: 10.2217/fon-2021-1054.

“Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018. Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E, Weiss T. *BMC Infectious Diseases* 2022 Mar; 22(1): 294. e-pub ahead of print 2022/03/30; doi: 10.1186/s12879-022-07275-9.

“Real-world treatment patterns in von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC): Costs of tumor reduction procedures and their complications.” Sundaram M, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Jonasch E. *Journal of Clinical Oncology* 2022 40(16\_suppl):4539-4539. doi: 10.1200/JCO.2022.40.16\_suppl.4539.

“A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.” Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S, Signorovitch J, Goemans N, McDonald CM, Mercuril E, Mendelld JR. *Journal of Neuromuscular Diseases* 2022 Jan; 9(1): 39-52. doi: 10.3233/JND-210665.

“The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.” Sieluk J, Song Y, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM. *Advances in Therapy* 2021 Dec. e-pub ahead of print 2021/12/18; doi: 10.1007/s12325-021-01913-5.

“Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes.” *Journal of Comparative Effectiveness Research* Oct; 10(14): 1065-1078. doi: 10.2217/cer-2021-0110.

“Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.” *Advances in Therapy* 2021 Apr; 38(4): 1946-1957. doi: 10.1007/s12325-021-01649-2.

“Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.” Healy BC, Glanz BI, Swallow E, Signorovitch J, Hagan K, Silva D, Pelletier C, Chitnis T, Weiner H. *Multiple Sclerosis Journal – Experimental, Translational and Clinical* 2021 Apr; 7(2): 2055217321999070. doi: 10.1177/2055217321999070.

“Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.” Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, Sherry N, Rejnmark L. *Advances in Therapy* 2021 Apr; 38(4): 1946-1957. doi: 10.1007/s12325-021-01649-2.

“Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19.” Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal N, Signorovitch J, Thune JJ, Vardeny O, Solomon SD. *JACC Heart Failure* 2021 Jan; 9(1): 65-73. doi: 10.1016/j.jchf.2020.11.00.

“Letter to the Editor Regarding ‘Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucelel versus Tisagenlecleucelel in Relapsed/Refractory Large B Cell Lymphoma.’” Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E. *Biology of Blood and Marrow Transplant* 2020 Dec; 26(12): e333-e334. doi: 10.1016/j.bbmt.2020.08.032.

“A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.” Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB. *Pharmacoeconomics* 2020 Nov; 38(11): 1201-1218. doi: 10.1007/s40273-020-00949-9.

“Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation: A United States payer perspective.” Muston DRG, Monberg MJ, McLaurin K, Sackeyfio A, Hettle R, Signorovitch J, Swallow E, Gao W, Zhang S, Kalemaj I, Moore KN. *Gynecologic Oncology* 2020 Oct; 159: 140-141. doi: 10.1016/j.ygyno.2020.05.186.

“Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.” Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandeborne K, Miller D, Ward SJ, Mercuri E. *Neurology* 2020 Sep 8; 95(10): e1381-e1391. doi: 10.1212/WNL.0000000000010170.

“Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.” Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM. *Current Medical Research and Opinion* 2020 Sep; 36(9):1507-1517. doi: 10.1080/03007995.2020.1799771. PMID: 32697113.

“A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.” Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB. *Pharmacoeconomics* 2020 Aug; e-pub ahead of print 2020 Aug 15; doi: 10.1007/s40273-020-00949-9.

“Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.” Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM. *Current Medical Research and Opinion* 2020:1; e-pub ahead of print 2020 Jul 23; doi: 10.1080/03007995.2020.1799771.

“Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.” Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandeborne K, Miller D, Ward SJ, Mercuri E. *Neurology* 2020 Jul; e-pub ahead of print 2020 Jul 03; doi: 10.1212/wnl.0000000000010170.

“Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis.” Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J. *Journal of Comparative Effectiveness Research* 2020 Jun; 9(10): 737-750; doi: 10.2217/ce-2020-0042.

“Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration.” Goemans N, Wong B, Van den Hauwe M, Signorovitch J, Sajeev G, Cox D, Landry J, Jenkins M, Dieye I, Yao Z, Hossain I, Ward SJ. *PloS One* 2020 Jun; 15(6): e0232870; doi: 10.1371/journal.pone.0232870.

“PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+)/human endocrine receptor negative (HER2-) metastatic breast cancer (mBC): A meta-analysis of published clinical trials.” Signorovitch J, Andre F, Wang R, Lorenzo I, Ridolfi A, Park J, Fillbrunn M,

Dua A, Rugo HS. *Journal of Clinical Oncology* 2020 05; 38(15\_suppl): 1069-1069. doi: 10.1200/JCO.2020.38.15\_suppl.1069.

“An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.” Bensimon AG, Zhou Z-Y, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R. *Clinical Drug Investigation* 2020 May; doi: 10.1007/s40261-020-00922-6.

“A Review of Two Regulatory Approved Anti-CD19 CAR T-cell Therapies in Diffuse Large B-Cell Lymphoma: Why are Indirect Treatment Comparisons Not Feasible?” Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E. *Advances in Therapy* 2020 May.

“Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.” Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG. *Blood Advances* 2020 Apr; 4(7): 1432-1439; e-pub ahead of print 2020 Apr 10; doi: 10.1182/bloodadvances.2019001304.

“Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.” Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL. *Blood Advances* 2020 Apr(7): 1440-1447; doi: 10.1182/bloodadvances.2019001305.

“Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.” Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J. *Journal of Comparative Effectiveness Research* 2020 Jan; doi: 10.2217/cer-2019-0169.

“Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.” Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL. *Journal of Comparative Effectiveness Research* 2020 Jan; e-pub ahead of print 2020 Jan 11; doi: 10.2217/cer-2019-0170.

“Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure—DANISH-MRI.” Elming MB, Hammer-Hansen S, Voges I, Nyktari E, Raja AA, Svendsen JH, Pehrson S, Signorovitch J, Køber L, Prasad SK, Thune JJ. *American Heart Journal* 2019 Dec; doi: <https://doi.org/10.1016/j.ahj.2019.10.020>.

“A composite prognostic score for time to loss of walking ability in Duchenne muscular dystrophy (DMD).” Goemans N, Signorovitch J, Sajeev G, Fillbrunn M, Wong H, Ward SJ, McDonald C, Mercuri E. *Value in Health* 2019 Nov; 22: S864; doi: 10.1016/j.jval.2019.09.2456.

“Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.” Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z. *Clinical Therapeutics* 2019 11; e-pub ahead of print 2019 Nov 09; doi: 10.1016/j.clinthera.2019.09.012.

“Pro4 Impact of Enzyme Replacement Therapy on the Risk of Developing Gaucher Disease-Related Complications.” Vera-Llonch M, Qi CZ, Swallow E, Zichlin ML, Signorovitch J. *Value in Health* 2019 Nov; 22: S841; doi: 10.1016/j.jval.2019.09.2336.

“Suitability of natural history data for external controls in Duchenne muscular dystrophy.” Goemans N, Wong B, Muntoni F, McDonald C, Mercuri E, Manzur A, Signorovitch J, Sajeev G, Wong H, Hossain I, Jenkins M, Ward SJ. *Value in Health* 2019 Nov; 22: S864; doi: 10.1016/j.jval.2019.09.2455.

“Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials.” McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, Peltz SW, Darras BT, Shieh PB, Cox DA, Landry J, Signorovitch J. *Muscle and Nerve* 2019 Oct; e-pub ahead of print 2019 Oct 11; doi: 10.1002/mus.26736.

“Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.” Queiroz Muniz D, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Lema Medina M, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S. *Advances in Therapy* 2019 Oct; e-pub ahead of print 2019/10/21; doi: 10.1007/s12325-019-01109-y.

“Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.” Muntoni F, Domingos J, Manzur AY, Mayhew A, Guglieri M, Sajeev G, Signorovitch J, Ward SJ. *PloS One* 2019 Sep; 14(9): e0221097; e-pub ahead of print 2019 Sep 04; doi: 10.1371/journal.pone.0221097.

“Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.” Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbaek L, Bruun NE, Eiskjaer H, Wiggers H, Brandes A, Thogersen AM, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Signorovitch J, Kober L, Thune JJ. *JACC Heart Failure* 2019 Aug; 7(8): 717-724; e-pub ahead of print 2019 Jul 16; doi: 10.1016/j.jchf.2019.03.019.

“Impact of hidradenitis suppurativa on work loss, indirect costs and income.” Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. *British Journal of Dermatology* 2019 Aug; 181(1): 147-154; e-pub ahead of print 2018 Aug 19; doi: 10.1111/bjd.17101.

“Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.” Levy BP, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M. *Current Oncology* 2019 June; 26(3): e300-e308; e-pub ahead of print 2019 Jul 10; doi: 10.3747/co.26.4485.

“The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.” Rorth R, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Bruun NE, Eiskjaer H, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Kober L, Kristensen SL. *Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology* 2019 Apr; e-pub ahead of print 2019 Jul 20; doi: 10.1093/europace/euz114.

“Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.” Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB. *Journal of Parenteral and Enteral Nutrition*. 2019 Apr; doi: <http://dx.doi.org/10.1002/jpen.1588>.

“Validation of an ambient measurement system (AMS) for physical activities in a paediatric population.” Varsanik JS, Kimmel ZM, Laforet GA, Ricotti V, Sajeev G, Signorovitch J, Quiroz JA, Chevalier TW. *Journal of Medical Engineering and Technology* 2019 Apr; 43(3): 182-189; e-pub ahead of print 2019 Jul 16; doi: 10.1080/03091902.2019.1640308.

“Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.” Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibanez R. *Journal of Medical Economics* 2019 Apr; 23: 1-13.

“Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.” Elming MB, Hammer-Hansen S, Voges I, Nyktari E, Raja AA, Svendsen JH, Pehrson S, Signorovitch J, Kober LV, Prasad SK, Thune JJ. *Circulation: Arrhythmia and Electrophysiology* 2019 Mar; 12(3): 1-9.

“Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis.” Fox E, Vieira MC, Johnson K, Peeples M, Bensimon AG, Signorovitch J, Herrera V. *Journal of the Neurological Sciences* 2019 Jan; 398: 163-170; e-pub ahead of print 2019 Feb 08; doi: 10.1016/j.jns.2019.01.036.

“Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.” Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A. *Journal of Medical Economics*. 2018 Nov;140-150.

“Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.” Bewley AP, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2018 Nov; 25.

“Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls.” Li J, Knoll S, Bocharova I, Tang W, Signorovitch J. *Current Medical Research and Opinion* 2018 10: 1-7.

“Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).” Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I. *Circulation* 2018 Oct; 138(14): 1387-1398.

“Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.” Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. *Cancer* 2018 Oct 15;124(20):4032-4043.

“Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.” Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. *Advances in Therapy* 2018 Sep; 35(10): 1564-1577.

“Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Income.” Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. *British Journal of Dermatology* 2018 Aug; 181: 147-154.

“Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome.” Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE. *Therapeutics and Clinical Risk Management* 2018 Aug; 14: 1267-1277.

“Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.”

Li J, Sasane M, Zhang J, Zhao J, Ricculli ML, Yao Z, Redhu S, Signorovitch J. *BMJ Open* 2018 Aug; 8(8): e021642.

“Epilepsy treatment patterns among patients with tuberous sclerosis complex.” Song J, Swallow E, Said Q, Peebles M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S. *Journal of the Neurological Sciences* 2018 Aug; 391: 104-108.

“Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.” Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ. *Current Medical Research and Opinion* 2018 Jun; 34(7): 1325-1333.

“Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis.” Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J. *Advances in Therapy* 2018 Jun: 1-14.

“Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers.” Chawla A, Peebles M, Li N, Anhorn R, Ryan J, Signorovitch J. *Journal of Medical Economics* 2018 Jun; 21(6): 543-552.

“Comparison of 3-year estimated glomerular filtration rates between recombinant human parathyroid hormone (1-84) (RHPH[1-84])-treated patients with chronic hypoparathyroidism and a historical control cohort.” Chen K, Mu F, Swallow E, Zhao J, Wang J, Krasner A, Sherry N, Signorovitch J. *Endocrine Practice* 2018 Apr; 24 (Supplement 1): 111.

“Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.” Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V. *Journal of the Neurological Sciences* 2018 Apr; 388: 168-174.

“Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.” Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE. *Value in Health* 2018 Jan; 21(1): 1-8.

“Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?” Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S. *CNS Drugs* 2017 Oct; 31(10): 899-910.

“Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.” Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM, Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Kober L, Thune JJ. *Circulation* 2017 Sep; 136(19): 1772-1780.

“Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.” Swallow E, King S, Song J, Peebles M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S. *Urology*. 2017 Jun;104:110-114.

“Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.” Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ. *International Journal of Urology*. 2017 Apr;24(4):272-278.

“Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.” Yang M, Galebach PJ, Signorovitch JE, Garg V. *Clinical and Experimental Rheumatology*. 2017 Mar 23.

“Comparative efficacy of long-acting  $\beta_2$ -agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.” Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE. *International Journal of Chronic Obstructive Pulmonary Disease*. 2017 Jan 19;12:367-381.

“Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.” Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A. *Rheumatology and Therapy*. 2016 Dec;3(2):305-322.

“Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.” Tundia N, Kotze PG, Rojas Serrano J, Mendes de Abreu M, Skup M, Macaulay D, Signorovitch J, Chaves L, Chao J, Bao Y. *Journal of Medical Economics*. 2016 Dec;19(12):1187-1199.

“Association between time to progression and subsequent survival in crizotinib-treated patients with advanced ALK-positive non-small-cell lung cancer.” Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J. *Current Medical Research and Opinion*. 2016 Nov;32(11):1911-1918.

“Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.” Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J; Collaborative Trajectory Analysis Project (cTAP). *PLoS One*. 2016 Oct 13;11(10):e0164684.

“Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.” Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. *Journal of the American Academy of Dermatology*. 2016 Oct;75(4):740-6.

“Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.” Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ; DMD Italian Group; Trajectory Analysis Project (cTAP). *Neuromuscular Disorders*. 2016 Sep;26(9):576-83.

“Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.” Tan DS, Araújo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G. *Journal of Thoracic Oncology*. 2016 Sep;11(9):1550-7.

“Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.” Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F. *Journal of Comparative Effectiveness Research*. 2016 May;5(3):273-9.

“Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.” Tan D, Liu G, Kim DW, Thomas M, Felip E, Signorovitch J, Zhang J, Szczudlo T, Shaw AT. *Journal of Thoracic Oncology* 2016 Apr;11(4): S134-S135.

“The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.” Zhang J, Song Y, Zhou ZY, Zhang C, Signorovitch J. *Journal of Thoracic Oncology* 2016 Apr;11(4): S119-S120.

“Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.” Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ. *Clinical Genitourinary Cancer*. 2016 Apr;14(2):160-7.e3.

“Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.” Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J. *Journal of Comparative Effectiveness Research*. 2016 Mar;5(2):129-39.

“Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.” Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peoples M, Mu F, Ackerman P, Signorovitch J. *Clinical Therapeutics*. 2016 Feb;38(2):404-12.

“Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.” Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ. *Cancer Medicine*. 2016 Feb;5(2):209-20.

“Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.” Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R. *Neurological Sciences*. 2016 Feb;37(2):165-79.

“Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.” Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E. *Current Medical Research and Opinion*. 2016;32(4):741-7.

“An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.” Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A. *Current Medical Research and Opinion*. 2016;32(4):721-9.

“Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.” Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ. *Journal of Medical Economics*. 2016;19(5):462-8.

“Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.” Nazareth T, Li N, Marynchenko M, Zhou Z, Chopra P, Signorovitch J, Wu E, Ahmed S, Marvel J, Sasane R. *Current Medical Research and Opinion*. 2016;32(3):405-16.

“Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.” Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Signorovitch JE, Healy BC, Chitnis T, Weiner HL, Bakshi R. *Journal of Neurology*. 2015 Nov;262(11):2425-32.

“The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.” Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R. *Journal of Neurological Science*. 2015 Oct 15;357(1-2):8-18.

“Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.” Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH. *Value Health*. 2015 Sep;18(6):824-31.

“Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer.” Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ. *Breast Cancer: Basic and Clinical Research*. 2015 Sep 3;9:67-72.

“Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis.” Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE. *RMD Open*. 2015 May 21;1(1):e000080.

“Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.” Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A. *Journal of Comparative Effectiveness Research*. 2015:1-13.

“Health resource use and costs of vilazodone and other selective serotonin reuptake inhibitors in treating major depressive disorder.” Zhou ZY, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J. *Journal of Medical Economics*. 2015:1-36.

“Everolimus Use and Associated Factors among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer.” Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ. *Current Medical Research and Opinion*. 2015:1-32.

“Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.” Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA. *Current Medical Research and Opinion*. 2015;31(6):1095-103.

“Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.” Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ. *Value in Health*. 2015;18(2):198-205.

“Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.” Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA, George DJ, Vogelzang NJ. *Expert Opinion on Pharmacotherapy*. 2015;16(6):805-19.

“Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.” Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C. *PLoS One*. 2014;9(12):e114264.

“Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.” Sweet D, Song J, Zhong Y, Signorovitch J. *Journal of the International AIDS Society*. 2014;17(4 Suppl 3):19537.

“One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.” Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ. *Current Medical Research and Opinion*. 2015;31(2):315-22.

“Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).” Macalalad AR,

Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C. *Current Medical Research and Opinion*. 2015;31(2):263-73.

“Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.” Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P. *British Journal of Dermatology*. 2015;172(2):504-12.

“Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.” Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H. *Journal of Medical Economics*. 2014;17(12):837-45.

“Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.” Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, Wong MK, Liu Z, Wang X, Culver K, Scott JA, Jonasch E. *Current Medical Research and Opinion*. 2014;30(11):2343-53.

“Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.” Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M. *British Journal of Dermatology*. 2014;171(6):1434-42.

“Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.” Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ. *Current Medical Research and Opinion*. 2014;30(10):2041-50.

“Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.” Bergman M, De G, Ganguli A, Signorovitch J, Bao Y. *Journal of Medical Economics*. 2015;18(1):37-44.

“Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.” Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M. *European Journal of Endocrinology*. 2014;171(1):89-98.

“Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.” Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. *Current Medical Research and Opinion*. 2014;30(8):1537-45.

“Pulmonary medication adherence and health-care use in cystic fibrosis.” Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA. *CHEST Journal*. 2014;146(1):142-51.

“Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.” Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ. *Current Medical Research and Opinion*. 2014;30(4):537-45.

“Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.” Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P. *Experimental Hematology & Oncology*. 2013;2(1):32.

“Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.” Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. *Cancer Treatment Reviews*. 2014;40(2):285-92.

“Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.” Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ. *CNS Drugs*. 2013;27(11):943-53.

“Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.” Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM. *Journal of the European Academy of Dermatology and Venereology*. 2014;28(6):790-8.

“Medical resource use and costs associated with chylomicronemia.” Gaudet D, Signorovitch J, Swallow E, Fan L, Tremblay K, Brisson D, Meyers C, Gruenberger JB. *Journal of Medical Economics*. 2013;16(5):657-66.

“A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.” Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L. *Pediatric Pulmonology*. 2013;48(10):954-61.

“Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.” Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM. *Diabetes, Obesity and Metabolism*. 2013;15(4):335-41.

“Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.” Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V. *Applied Health Economics and Health Policy*. 2012;10(6):381-95.

“Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.” Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ. *Value in Health*. 2012;15(6):940-7.

“Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.” Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ. *Pharmacoepidemiology and Drug Safety*. 2012;21 Suppl 2:130-7.

“Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.” Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. *Journal of Medical Economics*. 2012;15(6):1078-87.

“Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.” Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S. *Current Medical Research and Opinion*. 2012;28(4):591-9.

“Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.” Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM. *Current Medical Research and Opinion*. 2012;28(1):79-87.

“Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.” Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB. *Clinical Drug Investigation*. 2011;31(9):665-74.

“Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.” Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. *Pediatric Pulmonology*. 2012;47(1):44-52.

“The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.” Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM. *Journal of the American Academy of Dermatology*. 2012;66(2):e67-76.

“Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.” Signorovitch J, Brainsky A, Grotzinger KM. *Quality of Life Research*. 2011;20(10):1737-44.

“Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.” Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ. *Current Medical Research and Opinion*. 2011;27(6):1263-71.

“Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.” Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH. *Current Medical Research and Opinion*. 2011;27(6):1089-96.

“Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.” Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP, Kidolezi Y, Kelley D, Phillips G, Lawson A, Ball DE. *The Journal of Clinical Psychiatry*. 2011;72(6):787-94.

“Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.” Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD. *European Journal of Heart Failure*. 2011;13(2):148-53.

“Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.” Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Journal of the American Academy of Dermatology*. 2010;63(6):1011-8.

“Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.” Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM. *Clinical Drug Investigation*. 2011;31(1):51-60.

“Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.” Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM. *Pharmacoeconomics*. 2010;28(10):935-45.

“Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.” Simpson RJ, Jr., Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A. *American Journal of Therapeutics*. 2011;18(6):436-48.

“Phylogeny and biogeography of Hydra (Cnidaria: Hydridae) using mitochondrial and nuclear DNA sequences.” Martinez DE, Iniguez AR, Percell KM, Willner JB, Signorovitch J, Campbell RD. *Molecular Phylogenetics and Evolution*. 2010;57(1):403-10.

“The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.” Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P. *Journal of the American Academy of Dermatology*. 2010;62(5):812-8.

“Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.” Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH. *Current Medical Research and Opinion*. 2010;26(4):849-60.

“Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.” Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D. *Current Medical Research and Opinion*. 2010;26(2):355-63.

“Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.” Wu E, Guo A, Williams D, Guérin A, Yu A, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin J, Bollu V. *Journal of Clinical Oncology (Meeting Abstracts)* 2009 May; 27(15S): 7092.

“Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.” Simpson RJ, Jr., Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A. *Mayo Clinic Proceedings*. 2009;84(12):1065-72.

“Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.” Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Dermatology*. 2010;220(1):1-7.

“Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.” Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD. *European Heart Journal*. 2009;30(18):2226-32.

“Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.” Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. *Hypertension* 2008 Jan; 51(1): 48-54.

“Bladder cancer detection with CT urography in an Academic Medical Center.” Sadow CA, Silverman SG, O'Leary MP, Signorovitch JE. *Radiology*. 2008;249(1):195-202.

“Physiological importance of a circadian clock outside the suprachiasmatic nucleus.” Storch KF, Paz C, Signorovitch J, Raviola E, Pawlyk B, Li T, Weitz CJ. *Cold Spring Harbor Symposia on Quantitative Biology*. 2007;72:307-18.

“N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort.” Asselbergs FW, van den Berg MP, Bakker SJ, Signorovitch JE, Hillege HL, van Gilst WH, van Veldhuisen DJ. *Netherlands Heart Journal*. 2008;16(3):73-8.

“Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.” Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. *Hypertension*. 2008;51(1):48-54.

“Intrinsic circadian clock of the mammalian retina: importance for retinal processing of visual information.” Storch KF, Paz C, Signorovitch J, Raviola E, Pawlyk B, Li T, Weitz CJ. *Cell*. 2007;130(4):730-41.

“Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: results from the Roxbury lupus project.” Karlson EW, Watts J, Signorovitch J, Bonetti M, Wright E, Cooper GS, McAlindon TE, Costenbader KH, Massarotti EM, Fitzgerald LM, Jajoo R, Husni ME, Fossil AH, Pankey H, Ding WZ, Knorr R, Condon S, Fraser PA. *Arthritis & Rheumatology*. 2007;56(1):244-54.

“Correcting for ascertainment biases when analyzing SNP data: applications to the estimation of linkage disequilibrium.” Nielsen R, Signorovitch J. *Theoretical Population Biology*. 2003;63(3):245-55.

“PATRI-paternity inference using genetic data.” Signorovitch J, Nielsen R. *Bioinformatics*. 2002;18(2):341-2.

## **SELECTED PRESENTATIONS & SPEAKING ENGAGEMENTS**

“Evaluation of NT-proBNP as surrogate endpoint in AL amyloidosis: development of a platform for federated, multi-institution meta-analysis of randomized trials,” with Dispenzieri A, Maurer M, Huang X, Sanchorawala V, Dunmon P, Klersy C, Gambini G, Brown D, Barbachano Y, Adigun R, Hsu K, Lousada I, Xiu L, Faller D, Labotka R, Merlini G, Palladini G; XVIII International Symposium on Amyloidosis, September 4–8, 2022

“Projected impact of omidubicel on racial and ethnic disparities in allogeneic hematopoietic cell transplant access and outcomes for patients with hematologic malignancies in the US,” with Gergis U, Khara N, Edwards ML, Song Y, Sun R, Simantov R, Sivaraman S, and Manghani R; Transplantation & Cellular Therapy Tandem Meetings, April 23–26, 2022

“Factors influencing natural remission in chronic urticaria – preliminary results from a machine learning real-world study,” with Balp MM, Pivneva I, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang Y, Cornwall T, Pan J, Danyliv A, Marsland A, and Soong W; EAACI Hybrid Congress 2021, July 10–12, 2021

“Predicting time to natural remission in chronic urticaria using random survival forest model,” with Pivneva I, Balp MM, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang A, Cornwall T, Pan J, Danyliv A, Marsland A, and Soong W; EAACI Hybrid Congress 2021, July 10–12, 2021

“Productivity Costs Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer,” with Sieluk J, Haiderali A, Huang M, Hirshfield K, Signorovitch J, Song Y, Freimark J, Wang T; Virtual ISPOR 2021, May 17–20, 2021

“Real-World Treatment Patterns with Second-Generation Oral Antipsychotics Among People with Schizophrenia Insured by Medicaid,” with Garcia Horton V and Macaulay D; Academy of Managed Care Pharmacy Annual Meeting 2020, April 21–24, 2020

“A Phase 1b/2 study of RG6206 (BMS-986089) in boys with Duchenne muscular dystrophy: 72-week update,” with Dregheci R, Wagner KR, Wong BL, Byrne BJ, Tian C, Jacobsen LK, Tirucherai GS, Rabbia M, Kletzl H, Yen K, Sajeev G, Ward SJ, and Krishnan M; 61st Annual Meeting of the Japanese Society of Child Neurology, May 31–June 2, 2019

“Matching Adjusted Indirect Comparisons: Recommendation for the Selection of Baseline Characteristics Used for Matching,” with Gao W, Patterson-Lomba O, Wu EQ, and Ayyagari R; International Society for Pharmacoeconomics & Outcomes Research 24th Annual International Meeting (ISPOR 2019), May 18–22, 2019

“Matching-Adjusted Indirect Comparison of Efficacy and Safety of Acalabrutinib Versus Ibrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma,” with Telford C, Kabadi S, Abhyankar S, Song J, Zhao J, and Yao Z; ISPOR 2019, May 18–22, 2019

“Early Predictors of Sjogren’s Syndrome: A Machine Learning Approach,” with Royer J, Pivneva I, Huber W, and Capkun G; ISPOR 2019, May 18–22, 2019

“Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with tisagenlecleucel on the JULIET study,” with Schuster SJ, Maziarz RT, Ericson SG, Rusch ES, Romanov VV, Locke FL, and Maloney DG; 60th Annual Meeting of the American Society of Hematology, December 1–4, 2018

“Grading of neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving tisagenlecleucel treatment in the JULIET study,” with Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Ericson SG, Maloney DG, and Locke FL; 60th Annual Meeting of the American Society of Hematology, December 1–4, 2018

“Ambulatory Function in Duchenne Muscular Dystrophy (Dmd): The Characteristic Trajectory and Variation across Individuals,” with Muntoni F, Sajeev G, Yao Z, Ward SJ, and Abrams KR; ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, November 10–14, 2018  
*Best Podium Presentation Award*

“Artificial Intelligence Assisted Literature Reviews: Key Considerations for Implementation in Health Care Research,” with Wu EQ, Royer J, Ayyagari R, and Thokala P; ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, November 10–14, 2018

“Real-world comparative effectiveness of treatment sequences in metastatic non-small cell lung cancer with squamous histology,” with Yang H, Levy BP, Patterson-Lomba O, Xiang CQ, and Parisi M; 8th European Lung Cancer Congress, April 11–14, 2018

“Treatment patterns and clinical characteristics among patients with tuberous sclerosis complex related angiomyolipomas,” with Swallow E, Song J, Peebles M, Meiselbach M, Said Q, Prestifilippo J, Wong M, Northrup H, Frost M, Korf B, and Sparagana S; 2017 International Research Conference on TSC and LAM, June 22–24, 2017

“Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. health plan population,” with Zhou Z, Ryan J, and Chawla A; ASCO Annual Meeting, June 2–6, 2017

“Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study,” with Janku F, Wheler JJ, Miller VA, Ryan J, Zhou Z, and Chawla A; ASCO Annual Meeting, June 2–6, 2017

“Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer,” with Sasane M, Li J, Zhang J, Zhao J, Ricculli ML, and Redhu S; 7th European Lung Cancer Conference, May 5–8, 2017

“Identifying higher-value subpopulations for treatment in heterogeneous rare diseases: An example study of early responders to teduglutide for short bowel syndrome,” with Chen K, Xie J, Tang C, Zhao J, Olivier C, and Jeppesen PB; ISPOR 19th Annual European Congress, October 29–November 2, 2016

“M.S. Patients’ Willingness to Pay for a Subcutaneous Injection Device That Reduces Injection Site Pain in the Treatment of Psoriasis,” with Cividino A, Mittal M, and Yang M; 25th European Academy of Dermatology and Venereology, September 28–October 2, 2016

“Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis,” with Vogelzang NJ, Swallow E, Peeples M, Koo V, Perez JR, Ghate S, and Pal SK; ASCO Annual Meeting, Jun 3–7, 2016

“Measuring opportunities to improve health outcomes via individualized treatment assignment,” with Patterson-Lomba O; ISPOR 21st Annual International Meeting, May 21–25, 2016

“Epilepsy treatment patterns among patients with tuberous sclerosis complex,” with Sparagana S, Swallow E, Song J, King S, Peeples M, Liu Z, Prestifilippo J, Kohrman M, Korf B, Krueger D, and Wong M; 68th Annual Meeting of the American Academy of Neurology, April 15–21, 2016

“The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer,” with Zhang J, Song Y, Zhou Z, and Zhang C; 6th European Lung Cancer Conference, April 13–16, 2016

“Development of a risk score to guide individualized treatment selection in attention-deficit/hyperactivity disorder,” with Grebla R, Setyawan J, Yang H, Cheng D, Cai X, Xie J, and Erder M; 16th International Congress of European Society for Child and Adolescent Psychiatry, Jun 20–24, 2015

“Assessment of salary growth in patients with ankylosing spondylitis treated with and without anti-tumor necrosis factor therapy,” with Deodhar A, Mittal M, Joshi A, Yang M, and Bao Y; European League Against Rheumatism Congress, Jun 10–13, 2015

“Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care,” with Sawicki G, Ayyagari R, Zhang J, Fan L, Swallow E, and Shi L; podium presentation, American Thoracic Society International Conference, May 18–23, 2015

“Economic evaluation of timely versus delayed use of anti-tumor necrosis factor (TNF) biologics in the treatment of psoriatic arthritis (PSA) in the US,” with Zhou Z, Griffith JM, Zhong Y, and Ganguli A; ISPOR 20th Annual International Meeting, May 16–20, 2015

“Indirect comparisons for single-arm trials or trials without common comparator arms: what methods are available, how have they been used and how can we evaluate results?” with Swallow ES, Kalsekar A, and Yuan Y; workshop, ISPOR 20th Annual International Meeting, May 16–20, 2015

“A practical model for early identification of response with methotrexate for moderate to severe psoriasis,” with Gordon K, Sundaram M, Arunajadai S, Xie M, Betts K, and Okun M; 73rd Annual Meeting of the American Academy of Dermatology, March 20–24, 2015

“Economic implications of flares among patients with early rheumatoid arthritis (ra),” with Betts K, Garg V, and Bao Y; Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, November 14–19, 2014

“The randomized blind start trial: Evaluation of a new study design for assessing clinical outcomes in rare and heterogeneous patient populations,” with Ayyagari R and Kakkis E; ISPOR 17th Annual European Congress, November 8–12, 2014

“Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized treatment allocations that optimize cost-effectiveness in real-world data,” with Betts KA, Meng X, Zhuo Y, Wu EQ, and Shi L; ISPOR 17th Annual European Congress, November 8–12, 2014

“Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment,” with Sweet D, Song J, and Zhong Y; International Congress of Drug Therapy in HIV Infection 2014, November 2–6, 2014

“One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison,” with Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ; presentation, ASCO Annual Meeting, June 30–July 3, 2014 (suppl abstract 7072)

“Identifying high-value treatment populations in clinical trials and real-world data,” with Shaw J, Betts K, and Wu EQ; workshop at the ISPOR 19th Annual International Meeting, May 31–June 4, 2014

“Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection,” with Sweet DE, Zhuo DY, and Macalalad AR; ISPOR 19th Annual International Meeting, May 31–June 4, 2014

“Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment,” with Sweet DE, Kim Y, Song J, and Zhong Y; ISPOR 19th Annual International Meeting, May 31–June 4, 2014

“Adjusted Indirect Comparisons with Propensity Score Weighting When Individual Patient Data are Unavailable for One Treatment Group: Large Sample Theory and a Simulation Study of Statistical Performance,” with Ayyagari R; 37th Annual Midwest Biopharmaceutical Statistics Workshop, May 19–21, 2014

“Baseline risk adjustment for indirect comparisons: a Frequentist approach and implications for causal inference,” with Betts K; 37th Annual Midwest Biopharmaceutical Statistics Workshop, May 19–21, 2014

“Which Newly-Diagnosed Diabetics Should Receive Dietary Counseling Services? Estimating Individualized Treatment Allocations That Optimize Cost-Effectiveness in Real-World Data,” with Betts K, Meng X, Shi L, Wu EQ, and Zhuo Y; presented at ISPOR 17th Annual European Congress, November 8–12, 2013

“Assessment of wage and salary growth in patients with rheumatoid arthritis (RA),” with Bergman MJ, De G, Ganguli A, and Bao Y; Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Oct 25-30, 2013

“Cost-effectiveness of different treatment sequences including adalimumab in the treat-to-target framework for early rheumatoid arthritis in Germany,” with Wolff M, Zhou ZY, Shaw JW, and Ganguli A; Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Oct 25-30, 2013

“Association between guideline-adherent imaging and overall survival following second-line targeted therapy for metastatic renal cell carcinoma,” with Lin PL, Pal SK, Jonasch E, Liu Z, Culver KW, Scott JA, and Vogelzang NJ; American Society of Clinical Oncology Annual Meeting, May 31–June 4, 2013

“Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio,” with Ayyagari R, Cheng D, Chopra P, and Wu EQ; podium presentation at ISPOR 18th Annual International Meeting, May 18–22, 2013

“Matching-adjusted indirect comparisons: A simulation study of statistical performance,” with Ayyagari R, Cheng D, and Wu EQ; poster at ISPOR 18th Annual International Meeting, May 18–22, 2013

“Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease,” with Kimball AB, Sundaram M, and Samuelson T; American Academy of Dermatology 71st Annual Meeting, Mar 1–5, 2013

“Detecting undiagnosed depression in patients with moderate to severe psoriasis: Development and validation of a risk score for use in dermatology,” with Cather JC, Sundaram M, Horn EJ, and Yang M; American Academy of Dermatology 71st Annual Meeting, Mar 1–5, 2013

“The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus,” with Ayyagari R, Ong SH, Rikun A, Gruenberger JB; 1st American Diabetes Association Middle East Congress, Dec 4–6, 2012

“Benefits of treat-to-target guideline compliance in patients with rheumatoid arthritis: A retrospective claims analysis,” with Bergman MJ, Shaw JW, Cifaldi MA, Guerin A, and Chopra P; Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Nov 9–14, 2012

“Patient-reported outcomes associated with achieving and maintaining low disease activity in rheumatoid arthritis,” with Bergman MJ, Shaw JW, Cifaldi M, De G, He T, and Ayyagari R; Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Nov 9–14, 2012

“Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone,” with Van Vollenhoven R, Shaw JW, Cifaldi MA, Wu EQ, Samuelson TM, Faust E, and Emery P; Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Nov 9–14, 2012

“Annual healthcare costs for patients with cystic fibrosis from a Medicaid perspective,” with Zhang J, Marynchenko M, Chopra P, Ohashi E, and Wu E; 26th Annual North American Cystic Fibrosis Conference, October 11–13, 2012

“Lower adherence to chronic pulmonary medications is associated with increased health service utilization in patients with cystic fibrosis,” with Quittner AL, Zhang J, Marynchenko M, Chopra P, and Riekert KA; 26th Annual North American Cystic Fibrosis Conference, October 11–13, 2012

“Pulmonary medication adherence among individuals with cystic fibrosis,” with Riekert KA, Zhang J, Marynchenko M, Chopra P, and Quittner AL; 26th Annual North American Cystic Fibrosis Conference, October 11–13, 2012

“Indirect comparisons and network meta-analysis,” a 1.5-day training seminar developed and presented by Analysis Group for the health economics and market access staff of a European drug maker, October 2012

“The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials,” with Burmester G, Emery P, Williams D, Valdes J, Bao Y, and Mulani PM; Annual European Congress of Rheumatology of the European League Against Rheumatism, June 6–9, 2012

“Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis,” with Nurmohamed MT, Bao Y, Mulani PM, and Furst DE; Annual European Congress of Rheumatology of the European League Against Rheumatism, June 6–9, 2012

“Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: a matching adjusted indirect comparison of randomized trials,” with Du X, Hebden T, Juday T, Swallow E, Uy J, and Xie J; podium presentation at the ISPOR 17th International Meeting, June 2–6, 2012

“Comparing outcomes from separate clinical trials,” seminar on comparative effectiveness research methods, Dana Farber Cancer Institute, Department of Biostatistics, March 15, 2012

“Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin,” with Diener M, Frier BM, Gruenberger JB, Macaulay D, Yan S, and Wu EQ; podium presentation at the Diabetes UK Professional Conference 2012, March 7–9, 2012

“Mixed and indirect treatment comparisons,” seminar, Harvard University, Department of Biostatistics, November 10, 2011

“Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis,” with Latremouille-Viau D, Sawicki G, Shi L, von Wartburg M, Wu EQ, and Zhang J; poster presentation, 25th NACFC Annual Meeting, November 3–5, 2011

“Comparative Effectiveness Research Using Matching-Adjusted Indirect Comparison: A Method for Improving the Reliability and Interpretability of Indirect Comparisons,” with Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P, and Erder MH; podium presentation, Agency for Healthcare Research and Quality (AHRQ) Invitational Symposium on Research Methods for Comparative Effectiveness (CER) and Patient-Centered Outcomes Research (PCOR), June 6–7, 2011

“Utilizing rich data sources to identify patients’ subgroups that can benefit most from a treatment,” with Betts K, Erder MH, Hodgkins P, Setyawan J, Wei LJ, Wu EQ, Xie J, and Yang H; workshop, Agency for Healthcare Research and Quality (AHRQ) Invitational Symposium on Research Methods for Comparative Effectiveness (CER) and Patient-Centered Outcomes Research (PCOR), June 6–7, 2011

“Improved indirect treatment comparisons for comparative effectiveness research,” with Betts K, Navarro R, and Wu EQ; workshop, ISPOR 16th Annual International Meeting, May 21–25, 2011

“Planning and creating your value proposition: the role of comparative effectiveness data and indirect comparisons Leaf-Herrmann W,” Center for Business Intelligence (CBI) symposium on market access, April 2011

“Comparative effectiveness research for personalized medicine,” with Wei LJ and Wu EQ; workshop, ISPOR 15th Annual International Meeting, May 15–19, 2010

“Robust comparative effectiveness research without head-to-head trials: leveraging primary clinical trial data for indirect comparisons,” International Health Economics Association (IHEA) Annual Conference, July 12–15, 2009

“Comparative Effectiveness without Head- To- Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data,” with Wu EQ and Yu A; workshop, ISPOR 14th Annual International Conference, May 16–20, 2009